CUSIP: G4444C102
Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
11,425,219
-
Share change
-
+29,927
-
Total reported value
-
$112,817,466
-
Price per share
-
$9.89
-
Number of holders
-
45
-
Value change
-
+$259,064
-
Number of buys
-
16
-
Number of sells
-
16
Quarterly Holders Quick Answers
What is CUSIP G4444C102?
CUSIP G4444C102 identifies HLXA - MOONLAKE IMMUNOTHERAPEUTICS - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q1 2022
-
Previous quarter:
Q3 2021
Recent filing periods for CUSIP G4444C102:
Institutional Holders of MOONLAKE IMMUNOTHERAPEUTICS - COM (HLXA) as of Q4 2021
As of 31 Dec 2021,
MOONLAKE IMMUNOTHERAPEUTICS - COM (HLXA) was held by
45 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
11,425,219 shares.
The largest 10 holders included
FMR LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., PRICE T ROWE ASSOCIATES INC /MD/, BlackRock Inc., CITADEL ADVISORS LLC, 683 Capital Management, LLC, STALEY CAPITAL ADVISERS INC, MARSHALL WACE, LLP, Cormorant Asset Management, LP, and BOXER CAPITAL, LLC.
This page lists
45
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.